Please note: AABB reserves the right to make updates to this program.
This eCast is complimentary to AABB individual members through the generous support of Terumo BCT.
Thursday, March 12, 2020
2:00 – 3:00 PM (ET) 7:00 – 8:00 PM (GMT)
Master Program Number: 20EL-516 (see program format numbers below under Registration)
Educational Track: Technical/Clinical
Topic: Transfusion Medicine
Intended Audience: Directors, Hospitals, Hospital Blood Banks, Laboratory Staff, Managers/Supervisors, Medical Directors, Nurses, Perfusionists, Physicians, Research Scientists, Residents/Fellows, Scientists, Students (MD, MT, SBB), Transfusion Safety Officers
Teaching Level: Intermediate to Advanced
Moderator: Anna Razatos, PhD, Senior Manager, Global Scientific Marketing, Terumo BCT, Lakewood, CO
Peter Schubert, MSc, PhD, Clinical Associate Professor, Department of Pathology and Laboratory Medicine, University of British Columbia; Research Associate, Canadian Blood Services, Vancouver, British Columbia, Canada;
Pampee Young, MD, PhD, Chief Medical Officer, Biomedical Services, American Red Cross, Brentwood, TN
After participating in this educational activity, participants should be able to:
- Describe how LR WB will be used in the U.S. and its intended use in Canada.
- Discuss the validation data for platelet, plasma and RBC from Canadian in vitro study.
- Define the use of LR WB in active and massive bleeding and its flexibility in other applications.
Dr. Pampee Young (American Red Cross) and Dr. Peter Schubert (Canadian Blood Services) will discuss their findings on the use of leukoreduced whole blood (LR WB) in the U.S. and in Canada. They will demonstrate how both the U.S. and Canada are intending to use LR WB as well as supporting validation data.
This eCast (both live and on-demand) is complimentary to AABB individual members through the generous support of Terumo BCT; regular eCast registration fees apply for non-AABB members. Registration is required for AABB individual members and nonmembers.
| || ||
|Single Viewer: Live||
|Single Viewer: On-Demand||
Continuing Education Credit
AABB estimates both the live and on-demand version of this eCast each to be eligible for 1 continuing education credits/contact hours for California Nurse, California Lab Personnel, Florida Lab Personnel and General Participation credit. The final number of credit(s) and credit types awarded for this program (live or on-demand) will be determined by the program duration. Please note this program is not eligible for continuing medical education (CME) credit for physicians. For more information on each credit type please visit our
Continuing Education Credits webpage.
Dr. Peter Schubert received his PhD in biochemistry, molecular biology and microbiology at the University Erlangen, Germany. With two subsequent postdoctoral research appointments at the Biomedical Research Centre at UBC supported by a Michael Smith Foundation of Health Research award and the Canadian Institutes of Health Research/Heart and Stroke Foundation of Canada, he gained scientific training in cell biology and proteomics, respectively. Dr. Schubert currently serves as a Clinical Associate Professor in the Department of Pathology and Laboratory Medicine at UBC and as a Research Associate at Canadian Blood Services.
Dr. Pampee Young is the Chief Medical Officer of Biomedical Services of the American Red Cross. Dr. Young provides medical guidance, vision, and strategic direction focused on donor and patient safety objectives. As the unit with primary responsibility for the collection, processing, and distribution of blood and blood products, the American Red Cross’ Biomedical Services plays a critical role in our nation’s health care system. Dr. Young also provides leadership and support to the divisions of Scientific Affairs and Transfusion Innovations. Prior to joining the Red Cross, Dr. Young served as a tenured professor and medical director of Transfusion Medicine and the Stem Cell Laboratory at Vanderbilt University Medical Center in Nashville. Dr. Young also led a successful, funded basic research program focused on Wnt pathway in tissue repair. Her scientific group’s findings have resulted in over 80 peer reviewed original research publications and several patents. Dr. Young is committed to developing innovative approaches to patient care and safety, blood and cellular therapies accessibility, population health, and biomedical research.